What Namenda Does
Namenda (memantine) is an NMDA receptor antagonist FDA-approved for treating moderate to severe Alzheimer's disease, where it provides modest improvements in cognition, global function, and activities of daily living. 1
Mechanism of Action
Memantine works by blocking excessive glutamate activity at N-methyl-D-aspartate (NMDA) receptors in the brain. In Alzheimer's disease, chronic overstimulation of these receptors leads to excessive calcium influx and neuronal damage. Memantine acts as an uncompetitive, voltage-dependent antagonist with moderate affinity and fast on/off kinetics, preferentially blocking pathological overactivation while preserving normal physiological signaling needed for learning and memory 2, 3.
FDA-Approved Indication
Namenda is indicated specifically for moderate to severe dementia of the Alzheimer's type 1. This corresponds to patients with Mini-Mental State Examination (MMSE) scores between 3 and 14, or Global Deterioration Scale stages 5-6 1.
Standard Dosing Regimen
Immediate-release formulation:
- Start at 5 mg once daily
- Increase weekly by 5 mg/day in divided doses
- Target dose: 20 mg/day (10 mg twice daily) 1
- Treatment duration in trials: 24-28 weeks
Extended-release formulation:
- Available as 28 mg once-daily capsule
- Approved in 2010 for improved adherence
- Capsules can be opened and sprinkled on applesauce for patients with swallowing difficulties 4, 5
Clinical Efficacy by Disease Severity
Moderate-to-Severe Alzheimer's Disease (MMSE 3-14)
This is where memantine demonstrates clear benefit 6, 7:
- Cognition: Improvement of 3.11 points on Severe Impairment Battery (SIB) compared to placebo
- Global function: 0.21 points improvement on CIBIC-plus scale
- Activities of daily living: 1.09 points improvement on ADL19 scale
- Behavior: 1.84 points reduction on Neuropsychiatric Inventory
The evidence quality is high, with consistent results across 14 studies involving approximately 3,700 participants 7. Benefits occur whether memantine is used alone or combined with cholinesterase inhibitors 6.
Mild Alzheimer's Disease (MMSE 20-23)
Memantine shows no benefit in mild AD 8. Moderate-certainty evidence from four studies in 600 participants demonstrates no difference from placebo in cognition, activities of daily living, or behavior 8. Despite this, memantine is commonly prescribed off-label for mild AD in the United States—a practice not supported by evidence 2, 8.
Combination Therapy
Memantine can be safely combined with cholinesterase inhibitors (donepezil, rivastigmine, galantamine). One pivotal trial showed that adding memantine to ongoing cholinesterase inhibitor therapy provided additional benefit in moderate-to-severe AD 1. The combination is well-tolerated and may represent optimal pharmacologic management 9.
Effect Size Context
Important caveat: While statistically significant, the cognitive improvements with memantine do not consistently reach the threshold considered clinically meaningful 6. The ADAS-cog effect size is smaller than what experts define as clinically important 6. However, benefits in quality of life, caregiver burden, and delayed institutionalization add meaningful value beyond cognitive scores alone 6, 10.
Safety Profile
Memantine is well-tolerated with a favorable safety profile 6:
- Discontinuation rate: 9-12% (similar to placebo at 7-13%)
- Common adverse events: Dizziness (6.1% vs 3.9% placebo), headache (5.5% vs 4.3% placebo), gastrointestinal symptoms
- Protective effect: Less agitation reported in treatment groups compared to placebo 6
- No serious hepatotoxicity: Unlike tacrine, memantine does not cause liver damage 6
Other Dementia Types
Vascular dementia: Moderate-certainty evidence shows probable small benefit in cognition (2.15 ADAS-Cog points) and behavior, but no difference in global function or ADL 8
Lewy body dementia/Parkinson's disease dementia: Limited low-certainty evidence suggests possible benefit in global function 8, 11
Frontotemporal dementia: Insufficient evidence (only two small studies) 8
Clinical Bottom Line
Use memantine for moderate-to-severe Alzheimer's disease (MMSE 3-14) where high-quality evidence supports modest but consistent benefits across multiple domains. Do not use it for mild AD (MMSE 20-23) where evidence shows no benefit and potential for increased adverse events. Consider combination with cholinesterase inhibitors for additive effect. The standard target dose is 20 mg/day immediate-release (10 mg twice daily) or 28 mg/day extended-release (once daily) 7, 11.